What's Happening?
Medicare's stand-alone prescription drug plans (PDPs) are experiencing significant challenges, including higher premiums and a substantial reduction in available options for beneficiaries. Between 2023 and 2026, the number of PDPs decreased by 55%, from
804 to 360 plans. This decline is partly attributed to the Inflation Reduction Act of 2022 (IRA), which restructured Part D benefits. The IRA increased the generosity of standard benefits, improving affordability for many but also leading to higher drug spending. Additionally, the IRA shifted greater financial liability to Part D plan sponsors, making their benefit costs less predictable. In 2025, Medicare significantly reduced its reinsurance payments to plans while increasing direct-subsidy payments, forcing plans to bear risk on 60% of brand-name drug spending above the out-of-pocket (OOP) cap, compared to 15% previously. This change, coupled with a lowered OOP cap, has created uncertainty for plans regarding future prescription fills and overall costs. The average monthly premium for PDPs in 2026 is $36, significantly higher than the average of $8 for Medicare Advantage prescription drug plans (MA-PDs), with 75% of MA-PD enrollees paying no premium.
Why It's Important?
The instability in the PDP market has critical implications for Medicare beneficiaries, particularly those who choose traditional Medicare. The dwindling number of PDP options and their higher costs compared to MA-PDs could limit beneficiaries' ability to find suitable drug coverage that meets their specific needs. This disparity also erodes the competitiveness of traditional Medicare against Medicare Advantage plans, potentially pushing more beneficiaries towards MA-PDs due to lower premiums and broader availability. The increased financial risk for Part D plans may lead them to bid conservatively, resulting in higher premiums for beneficiaries or a further reduction in plan offerings. The shift in financial liability also means plans have fewer tools to manage drug spending, as a significant portion of spending now occurs in the catastrophic phase without cost-sharing. This situation could lead to higher program costs for taxpayers and increased out-of-pocket expenses for beneficiaries in the long run, undermining the original intent of providing affordable and accessible prescription drug coverage.
What's Next?
The temporary measures implemented to constrain premium growth, such as the IRA's cap on Part D premium increases through 2029 and CMS's premium stabilization demonstration ending this year, are set to expire. This expiration is expected to lead to sharp increases in beneficiary premiums starting in 2030. Without further policy changes, beneficiaries could face substantially higher premiums, and the number of available PDPs may continue to decline. Policymakers will need to consider new approaches to sustain the PDP market and ensure meaningful choices for beneficiaries. The ongoing uncertainty for plans regarding drug utilization and spending, especially with the introduction of Maximum Fair Prices (MFPs) for selected drugs in 2026, will likely influence future plan bids and offerings. The disparity in payment systems, where MA-PDs can use federal payment rebates to lower drug premiums, will continue to give them a competitive advantage over PDPs, potentially widening the premium gap further after the current temporary relief measures conclude.
Beyond the Headlines
The challenges facing Medicare Part D plans highlight a broader tension within the U.S. healthcare system regarding the balance between beneficiary affordability, plan financial stability, and market competition. The shift in financial risk to plans, while intended to incentivize better cost management, has introduced significant unpredictability, potentially leading to unintended consequences like reduced plan availability and higher costs for consumers. The competitive advantage of MA-PDs, fueled by federal subsidies and rebates, raises questions about equitable competition between traditional Medicare and Medicare Advantage. This dynamic could lead to a two-tiered system where beneficiaries in traditional Medicare face increasingly limited and expensive drug coverage options. The long-term implications include potential erosion of choice for seniors, increased reliance on Medicare Advantage, and ongoing debates about the sustainability and fairness of Medicare's various components. Addressing these issues will require a comprehensive re-evaluation of Part D's financial structure and the competitive landscape of prescription drug coverage.
